Where Can You Actually Get Semaglutide Microdosing? 4 Real Options in 2026

What actually counts as a semaglutide microdose?

Start with the branding confusion, because it trips up almost everyone searching this. Ozempic and Wegovy are both semaglutide — the exact same molecule — sold under two different names for two different approvals. Ozempic is FDA-approved for type 2 diabetes, with a dose ceiling of 2mg weekly. Wegovy is FDA-approved for chronic weight management, climbing to a 2.4mg weekly maintenance dose. Neither brand sells a product marketed as a "microdose." When a platform advertises semaglutide microdosing, it almost always means compounded semaglutide — a pharmacy-made version of the same active ingredient, prepared at a smaller amount than either brand's approved dose, under a prescriber's own titration plan rather than the FDA label.

There's no FDA definition of a microdose, so the number means whatever the platform selling it says it means. Noom puts a figure on it: 25% or less of a typical maintenance dose. Interestingly, at least one other provider selling a semaglutide microdose, Lemonaid Health, describes its own version the same way — a dose capped at roughly a quarter of standard maintenance — which suggests something closer to an informal industry convention is forming here, even without any regulatory standard behind it.

Where can you actually get semaglutide microdosing — four real, named options

Search "semaglutide microdosing" and most of what surfaces is content about the idea, not a product you can actually buy — Reddit threads, wellness blogs, and explainer articles. Strip those out and the list of platforms that sell a genuinely separate, priced, semaglutide-specific microdose SKU narrows to four.

Noom's Microdose GLP-1Rx — the deepest, most scrutinized option

Noom built the best-known branded version of this. Microdose GLP-1Rx is its own line item, distinct from Noom's standard GLP-1Rx tier ($249/mo) and its tirzepatide-based GLP-1Rx Plus tier ($299/mo) — both of which confirm the microdose program is semaglutide only. Current pricing runs $79 for the first four-week supply, then $199 a month afterward, though it isn't billed monthly at all: Noom charges it as a lump sum every 12 weeks, close to $597 a quarter. Budget for that upfront rather than assuming a smaller recurring charge.

Noom's own material describes the program's doses as commonly running from about 0.2mg up to a ceiling near 0.6mg weekly, set and adjusted individually through what the company calls its SmartDose process rather than a fixed chart every member follows. The claims around it drew real regulatory attention: in May 2026, the National Advertising Division reviewed a challenge from Eli Lilly — a direct competitor through its own Zepbound and Mounjaro brands — over Noom's tagline "A Smaller Dose. A Smarter Start." NAD found Noom hadn't substantiated the implication that a smaller dose delivers a measurable health benefit, and recommended the claim be dropped or reworked. Noom disagreed with the finding but agreed to comply.

Henry Meds — the cheapest dedicated microdose SKU

Henry Meds runs a dedicated microdose page separate from its standard semaglutide treatment, priced at $179 a month with provider visits, medication, and supplies folded into that single rate — no separate membership fee stacked on top. Of the four real options here, it's the cheapest dedicated microdose SKU — Mochi Health's blended flat-rate plan technically runs about a dollar a month lower, but only because it isn't its own product. Henry Meds also defines the approach in plainer terms than most: smaller, steadier doses meant to ease tolerability rather than chase a specific percentage figure.

Mochi Health — no separate SKU, and the lowest total price

Mochi Health takes a different approach entirely. It doesn't brand a separate microdose product the way Noom, Henry Meds, and Fridays do. Compounded semaglutide there is one flat $99 medication fee across its full dose range, plus a $79 membership, for about $178 all-in — the lowest total of the four, even without a dedicated SKU. A prescriber choosing to keep your dose lower and your titration slower doesn't change what you pay — it's simply the low end of the standard plan, not its own SKU.

Fridays — built for wellness framing, not weight loss

Fridays' Microdosing product line sits apart from its standard weight-loss semaglutide track, and it leans hardest into wellness language of the four: energy, metabolic balance, and steady focus rather than pounds lost. It's typically a daily oral compounded semaglutide formulation blended with other ingredients, priced on the same tiered structure as Fridays' regular plan — as low as $150 a month on an annual prepay, up to $249 month-to-month.

A couple of smaller platforms also sell a named semaglutide microdose product worth knowing about, even without a working link here yet. Lemonaid Health lists compounded semaglutide microdoses at $199 a month in medication plus a $49 membership, for about $248 all-in — and defines the dose the same way Noom does, capped at 25% of standard maintenance. WeightCare sells a Semaglutide Micro-Dose product starting around $249 a month with a one-time consult fee under $20, dosing from 0.25mg up to a 1mg weekly ceiling. Neither is tabled above because their pricing was less consistently confirmed across sources than the four platforms with a direct affiliate link — worth a direct check before you commit to either.

Two names worth ruling out specifically, since they show up constantly in searches for GLP-1 microdosing generally: Ro states plainly on its own site that it doesn't offer GLP-1 microdosing, sticking instead to FDA-approved brand-name Wegovy and Zepbound. And Hims wound down its compounded semaglutide entirely in the first half of 2026 after a legal dispute with Novo Nordisk over a $49 compounded offer — it now sells only branded Wegovy and Zepbound, at standard doses, not a microdose product. If you're seeing either name attached to "semaglutide microdosing" content, that's likely general education content, not something either company currently sells.

One more worth a mention for this audience specifically: Alloy Health, a menopause-focused platform, treats microdosing as a tailoring option inside its standard compounded semaglutide program — about $169 a month all-in ($70 medication, $99 membership) — rather than a separately priced product. Its physicians specialize in perimenopause and menopause specifically, which matters if you'd rather have someone who already understands your hormonal picture setting the pace. See Alloy's compounded semaglutide plan if that's the fit you want.

What does semaglutide microdosing actually cost — and what does a year of it add up to?

None of the four real options differs wildly once you annualize it, but the shape of the bill does. Henry Meds runs closest to $2,148 a year at its flat $179 monthly rate. Mochi Health lands near $2,136 a year for the same reason its price doesn't change with dose. Noom, despite its quarterly billing, works out to roughly $2,388 a year at $199 a month — plus its $79 first month. Fridays spans the widest range, from about $1,800 a year on its annual prepay up to nearly $2,988 a year paying month-to-month, which makes the commitment length the real lever on price there, not the dose itself.

None of these figures include labs if your prescriber orders them separately, and all four require compounded medication rather than an FDA-approved brand — a legal status worth understanding, covered further down. For the wider semaglutide pricing picture beyond just microdosing, the cheapest semaglutide providers compares six programs with every fee spelled out.

The FDA's Wegovy dose ladder, and where a microdose actually sits below it

Wegovy's real, approved escalation schedule is the reference point every microdose product is implicitly measured against, whether or not the marketing says so. It climbs in five steps to a 2.4mg maintenance dose over a minimum of 16 weeks. A compounded semaglutide microdose, in the sense these four platforms sell it, generally means staying well below even the first rung of that ladder — not just at the early tolerability steps, but under them.

For the full ladder, the oral tablet's separate schedule, and the missed-dose rules, see the complete semaglutide dosage guide.

How does the semaglutide microdosing protocol actually work?

In every legitimate version of this, a prescriber sets the number, not you. Noom's SmartDose process, its own term for individualizing dose within that 25%-or-less ceiling, still runs through a clinician review before anything ships. Henry Meds and Fridays both describe the same shape: an initial evaluation, a starting dose, and adjustments made by the platform's provider based on how you're tolerating it, not a printed chart you follow on your own.

Where the protocols genuinely differ is pacing. Some platforms position microdosing as a gentler on-ramp toward eventually climbing higher, closer to how the FDA schedule works but slower. Others, Fridays' wellness-framed product especially, position it as a place to stay long-term rather than a stepping stone — which is a meaningfully different use case, and worth clarifying with whichever platform you choose before you assume which one you're getting.

Is there real science behind semaglutide microdosing, or mostly a trend?

Mostly a trend, with a real mechanism underneath it. Semaglutide works on a single receptor — GLP-1 — unlike tirzepatide, which also activates the GIP receptor. That simpler, single-pathway mechanism is well understood pharmacologically, and it's part of why researchers can reasonably expect a dose-response relationship to hold at lower amounts too. What's missing is the trial that actually tested that expectation. The study that established Wegovy's effect, STEP-1, was built around reaching a 2.4mg maintenance dose, with a clear dose-response pattern at the doses studied — more drug, up to that ceiling, produced more weight loss. Deliberately staying well under the starting dose long-term wasn't the protocol STEP-1 tested, and there's no completed clinical trial specifically evaluating semaglutide microdosing for weight loss, inflammation, or any other outcome as of this writing.

That gap matters more here than it might for a smaller trend, because semaglutide microdosing is arguably the most commercially developed corner of the whole GLP-1 microdosing conversation — four real companies have built entire product lines and marketing around it. Commercial traction isn't the same thing as clinical evidence, and Noom's own May 2026 NAD outcome is a useful reminder of exactly that gap.

Are the side effects actually gentler at a semaglutide microdose — and does it still work?

Probably somewhat gentler, though not proven at the doses these platforms are selling. In the trials behind Wegovy's approval, nausea and GI side effects were heaviest right after each dose increase and eased with time — a pattern that lines up with expecting a smaller dose to feel easier, since there's less of an increase to adjust to. But that's an extrapolation from data collected at 0.25mg and above, not a measurement taken at 0.1mg or 0.2mg specifically. Noom cites its own internal figure — about 70% of its microdose members reporting no side effects — but that's company survey data from its own user base, not an independently measured trial result, and self-reported figures like that tend to run more favorable than clinical measurement typically does.

On effectiveness, the honest answer is less certain the lower you go. The weight-loss results documented in STEP-1 were measured at the 2.4mg maintenance dose. Staying meaningfully below that is an off-label choice with a thinner evidence base — some people do see real appetite and weight changes at lower doses, but how much benefit holds up at a quarter of the studied dose, consistently, isn't well established yet.

Can semaglutide microdosing help with inflammation or autoimmune symptoms?

This is the part of the pitch that deserves the most skepticism. GLP-1 receptors do exist on immune cells, and semaglutide's single-receptor mechanism has shown, in animal and cell-culture studies, an ability to lower inflammatory markers like TNF-alpha and IL-6. That's genuine mechanistic biology. It is a long way from a treatment for rheumatoid arthritis, Hashimoto's, lupus, or any other autoimmune condition in an actual person taking a fraction of a standard dose. There is no completed human clinical trial showing semaglutide microdosing improves an autoimmune or inflammatory disease outcome as of this writing — if that's the specific claim that drew you here, treat it as an open, unstudied question rather than a benefit you're purchasing.

Is this the right starting point for you in perimenopause?

If your GI system already feels more reactive than it used to — and a lot of women notice perimenopause turning up the volume on nausea and bloating that never bothered them before — a gentler on-ramp has real appeal, and a slower climb genuinely can mean fewer rough early weeks. It carries a related upside worth knowing: pacing weight loss more slowly tends to be easier on muscle, which matters more once estrogen decline is already working against your lean mass on its own. That specific tradeoff, and how to protect against it regardless of which dose you land on, is covered in GLP-1s and muscle loss in perimenopause.

The honest counterweight: choosing to stay at a fraction of the studied dose trades away some certainty about results for that gentler start. If meaningful weight or metabolic change is your main goal, climbing toward Wegovy's studied 2.4mg maintenance dose has the stronger evidence behind it. A slower climb toward that same destination — not necessarily stopping well short of it — is a middle path worth raising with your prescriber if side effects, not the outcome, are what worries you.

How to tell a legitimate low-dose protocol from a DIY red flag

The line that matters isn't the number on the dose — it's who's managing it. A legitimate microdose protocol comes from a licensed prescriber, filled through a named compounding pharmacy, with a dose your provider set and can adjust as you go. A red flag looks different: splitting a Wegovy or Ozempic pen yourself, buying an unlabeled "microdosing kit" online, or drawing your own reduced amount from a vial without specific instructions from anyone who's reviewed your history.

The FDA has already documented what goes wrong with the self-directed version. A July 2024 alert on compounded semaglutide dosing errors described patients accidentally injecting five to twenty times their intended dose after misreading units on a syringe, some requiring hospitalization — a risk that's specific to compounded vial-and-syringe formulations rather than the pre-filled Wegovy or Ozempic pen, which delivers a fixed, preset amount and isn't designed for splitting or repeated draws in the first place.

Compounded semaglutide's legal footing has also narrowed since the shortage years that once made it common everywhere. The FDA removed semaglutide from its drug shortage list in February 2025, which triggered wind-down deadlines for both 503A pharmacies and 503B outsourcing facilities compounding near-copies of the branded product. What remains is a narrower pathway: compounding for a specific, documented individual medical need the approved version can't meet, not simply because it's cheaper. In April 2026, the FDA went further, proposing to remove semaglutide, tirzepatide, and liraglutide from the 503B Bulks List entirely; the public comment period closed in late June 2026, and a final rule hadn't been issued as of this writing. If a seller can't name its compounding pharmacy or explain the specific clinical-need pathway it's using, that's the moment to walk away rather than adjust anything yourself.